Cartesian Therapeutics, Inc. (RNAC)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch RNAC
See up to 3 months of RNAC. The 7-day demo opens the 1M and 3M ranges and puts RNAC on your watchlist.
Start 7-day demoLatest RNAC insider trades
About Cartesian Therapeutics, Inc. (RNAC)
The SEC lists Cartesian Therapeutics, Inc. under CIK 0001453687, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
RNAC Form 4 activity by transaction type, last 90 days
No Form 4 activity for RNAC in the last 90 days.
RNAC insider transactions (Form 4)
9621 Form 4 filings on record, the earliest from Oct 4, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Elizabeth Hoge - 10% Owner | Option exercise | Common Stock | 758,001 | - footnote F1 | - | |
| Elizabeth Hoge - 10% Owner | Option exercise | Series A Non-Voting Convertible Preferred Stock | 22,740 | - footnote F3 | - | |
| ||||||
| Murat Kalayoglu - 10% Owner | Option exercise | Common Stock | 758,001 | - footnote F1 | - | |
| Murat Kalayoglu - 10% Owner | Option exercise | Series A Non-Voting Convertible Preferred Stock | 22,740 | - footnote F3 | - | |
| ||||||
| Michael Singer - Director | Gift | Common Stock | 6,555 | $0.00 | - | |
| Emily English - Officer | Option exercise | Common Stock | 7,500 | $3.30 | $25K | |
| Emily English - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | - footnote F2 | - | |
| ||||||
| Michael Singer - Director | Gift | Common Stock | 20,000 | $0.00 | - | |
| June Ann Seymour - Officer | Grant or award | Employee Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 7,342 | $9.43 | $69K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 31 | $9.95 | $308 | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 41,604 | $9.43 | $392K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 178 | $9.95 | $2K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 7,966 | $10.43 | $83K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 609 | $10.92 | $7K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 45,144 | $10.43 | $471K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 3,451 | $10.92 | $38K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 6,412 | $10.77 | $69K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 36,338 | $10.77 | $391K | |
| Emily English - Officer | Option exercise | Common Stock | 7,650 | $3.30 | $25K | |
| Emily English - Officer | Option exercise | Stock Option (Right to Buy) | 7,650 | - | - | |
| Michael Singer - Director | Gift | Common Stock | 20,000 | $0.00 | - | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 11,303 | $17.39 | $197K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 10,529 | $18.35 | $193K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 3,376 | $18.93 | $64K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 21,800 | $18.94 | $413K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 5,181 | $19.00 | $98K | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 10,763 | $1.41 | $15K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 6,224 | $25.26 | $157K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 4,539 | $25.83 | $117K | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 2,901 | $1.41 | $4K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 2,901 | $24.35 | $71K | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 10,763 | - | - | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 2,901 | - | - | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 200 | $1.41 | $282 | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 200 | $19.50 | $4K | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 5,700 | $1.41 | $8K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 5,600 | $17.28 | $97K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 100 | $18.09 | $2K | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 32,789 | $1.41 | $46K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 32,789 | $16.67 | $547K | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 200 | - | - | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 5,700 | - | - | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 32,789 | - | - | |
| Michael Singer - Director | Gift | Common Stock | 28,821 | $0.00 | - | |
| Christopher M. Jewell - Officer | Option exercise | Common Stock | 14,000 | $3.23 | $45K | |
| Christopher M. Jewell - Officer | Option exercise | Stock Option (Right to Buy) | 14,000 | - | - | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 74,157 | $16.19 | $1.20M | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 22,242 | $16.97 | $377K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 277,246 | $17.09 | $4.74M | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 38,114 | $17.96 | $684K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 20,181 | $18.42 | $372K | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 25,900 | $1.41 | $37K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 21,900 | $16.33 | $358K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 4,000 | $17.06 | $68K | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 22,068 | $1.41 | $31K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 22,068 | $17.20 | $379K | |
| Metin Kurtoglu - Officer | Option exercise | Common Stock | 34,400 | $1.41 | $49K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 16,672 | $18.19 | $303K | |
| Metin Kurtoglu - Officer | Open-market sale | Common Stock | 17,728 | $18.58 | $329K | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 25,900 | - | - | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 22,068 | - | - | |
| Metin Kurtoglu - Officer | Option exercise | Stock Option (Right to Buy) | 34,400 | - | - | |
| Milos Miljkovic - Officer | Option exercise | Common Stock | 35,000 | $3.23 | $113K | |
| Milos Miljkovic - Officer | Open-market sale | Common Stock | 35,000 | $16.13 | $565K | |
| Milos Miljkovic - Officer | Option exercise | Common Stock | 20,000 | $3.23 | $65K | |
| Milos Miljkovic - Officer | Open-market sale | Common Stock | 20,000 | $17.14 | $343K | |
| Milos Miljkovic - Officer | Option exercise | Stock Option (Right to Buy) | 35,000 | - | - | |
| Milos Miljkovic - Officer | Option exercise | Stock Option (Right to Buy) | 20,000 | - | - | |
| Christopher M. Jewell - Officer | Option exercise | Common Stock | 36,050 | $3.23 | $116K | |
| Christopher M. Jewell - Officer | Open-market sale | Common Stock | 18,550 | $16.34 | $303K | |
| Christopher M. Jewell - Officer | Open-market sale | Common Stock | 17,500 | $17.02 | $298K | |
| Christopher M. Jewell - Officer | Option exercise | Common Stock | 16,065 | $3.23 | $52K | |
| Christopher M. Jewell - Officer | Open-market sale | Common Stock | 16,065 | $17.06 | $274K | |
| Christopher M. Jewell - Officer | Option exercise | Stock Option (Right to Buy) | 36,050 | - | - | |
| Christopher M. Jewell - Officer | Option exercise | Stock Option (Right to Buy) | 16,065 | - | - | |
| Murat Kalayoglu - Director | Option exercise | Common Stock | 1,518,373 | - | - | |
| Murat Kalayoglu - Director | Option exercise | Series A Non-Voting Convertible Preferred Stock | 45,551 | - | - | |
| Elizabeth Hoge - 10% Owner | Option exercise | Common Stock | 1,518,373 | - | - | |
| Elizabeth Hoge - 10% Owner | Option exercise | Series A Non-Voting Convertible Preferred Stock | 45,551 | - | - | |
| Timothy A. Springer - Director | Other | Common Stock | 1,801,314 | - | - | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 5,514 | $17.38 | $96K | |
| Timothy A. Springer - Director | Other | Common Stock | 2,119,193 | - | - | |
| Timothy A. Springer - Director | Other | Common Stock | 317,879 | - | - | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 29,847 | $18.25 | $545K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 10,249 | $19.01 | $195K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 50,489 | $20.18 | $1.02M | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 21,278 | $21.17 | $451K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 8,043 | $21.86 | $176K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 9,892 | $21.35 | $211K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 48,880 | $22.35 | $1.09M | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 16,650 | $23.57 | $392K | |
| Timothy A. Springer - Director | Open-market purchase | Common Stock | 4,879 | $23.93 | $117K | |
| Timothy A. Springer - Director | Other | Warrant (Right to Buy) | 133,632 | - | - | |
| Timothy A. Springer - Director | Other | Warrant (Right to Buy) | 113,587 | - | - | |
| Timothy A. Springer - Director | Other | Warrant (Right to Buy) | 20,045 | - | - | |
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Item 5.07
Item 7.01, 9.01
Recent RNAC Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
RNAC insider trading FAQ
What is the latest insider trade for RNAC?
Cartesian Therapeutics, Inc. (RNAC) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-04-06. The full record for RNAC runs to 21 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RNAC stock?
No insider purchases of RNAC were filed in the last 90 days. 30 purchases are on record for this company.
How many insiders are selling RNAC stock?
No insider sales of RNAC were filed in the last 90 days. 17 sales are on record for this company.
Where can I see RNAC SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RNAC Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Elizabeth Hoge view on EDGAR
- - Murat Kalayoglu view on EDGAR
- - Michael Singer view on EDGAR
- - Emily English view on EDGAR
- - Michael Singer view on EDGAR
- - June Ann Seymour view on EDGAR
- - Timothy A. Springer view on EDGAR
- - Emily English view on EDGAR
- - Michael Singer view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RNAC's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RNAC with a 7-day demo
- RNAC on your watchlist
- Every RNAC Form 4 filing on record
- Up to 3 months of RNAC price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
